Clinical Trials Browser

Recruiting × Lung Neoplasms × osimertinib × Clear all

NCT04181060 2026-06-03

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT05642572 2026-06-03

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05401110 2026-05-07

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06014827 2026-05-07

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06618287 2026-05-07

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT04591002 2026-04-30

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

Phase 2 Recruiting

Lung Neoplasms

NCT07295821 2026-04-08

NSCLC

Phase 2 Recruiting

Lung Neoplasms

NCT04762199 2026-03-31

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06538038 2026-03-27

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07379476 2026-02-12

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07315113 2026-01-02

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04780568 2025-12-09

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06574347 2025-05-21

KYLIN-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06383728 2024-05-09

GALAXY-02

Phase 2 Recruiting

Carcinoma, Squamous Cell, Lung Neoplasms